CCM
REGN icon

Crew Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Crew Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-454
Closed -$288K – 149
2025
Q1 		$288K Sell
454
-10
-2% -$6.88K 0.24% 115
2024
Q4 		$331K Sell
464
-302
-39% -$253K 0.27% 101
2024
Q3 		$805K Buy
+766
New +$852K 0.64% 61
2024
Q1 		– Sell
-375
Closed -$329K – 126
2023
Q4 		$329K Buy
+375
New +$309K 0.34% 61

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Crew Capital Management's REGN Position: Q2 2025 in Review

Crew Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 454 shares — an estimated $288K sold.

Crew Capital Management first reported a position in REGN in Q4 2023 and held it in 4 quarters. The position peaked at $805K in Q3 2024. 1,203 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Crew Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Crew Capital Management sold 454 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $288K.
  • Crew Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Crew Capital Management's Regeneron Pharmaceuticals position peaked at $805K in Q3 2024.
  • 1,203 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Crew Capital Management's 13F filing for Q2 2025, filed 14 Jul 2025.